The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%
|
|---|---|
| Published in |
Frontiers in oncology, August 2022
|
| DOI | 10.3389/fonc.2022.980765 |
| Pubmed ID | |
| Authors |
Ilaria Attili, Carmine Valenza, Celeste Santoro, Gabriele Antonarelli, Pamela Trillo Aliaga, Ester Del Signore, Chiara Catania, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 12 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 33% |
| Student > Ph. D. Student | 1 | 8% |
| Unspecified | 1 | 8% |
| Student > Bachelor | 1 | 8% |
| Other | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 4 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 17% |
| Unspecified | 1 | 8% |
| Economics, Econometrics and Finance | 1 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
| Unknown | 7 | 58% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2022.
All research outputs
#23,491,956
of 26,169,168 outputs
Outputs from Frontiers in oncology
#16,369
of 22,913 outputs
Outputs of similar age
#371,417
of 437,064 outputs
Outputs of similar age from Frontiers in oncology
#1,360
of 1,809 outputs
Altmetric has tracked 26,169,168 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,064 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,809 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.